- Home
- ADIL vs IMRN Comparison
ADIL vs IMRN Comparison
Compare ADIL & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- IMRN
- Stock Information
- Founded
- ADIL 2010
- IMRN 1994
- Country
- ADIL United States
- IMRN Australia
- Employees
- ADIL N/A
- IMRN N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- IMRN Health Care
- Exchange
- ADIL Nasdaq
- IMRN Nasdaq
- Market Cap
- ADIL 7.7M
- IMRN 9.2M
- IPO Year
- ADIL 2018
- IMRN N/A
- Fundamental
- Price
- ADIL $0.40
- IMRN N/A
- Analyst Decision
- ADIL Strong Buy
- IMRN
- Analyst Count
- ADIL 2
- IMRN 0
- Target Price
- ADIL $4.75
- IMRN N/A
- AVG Volume (30 Days)
- ADIL 745.4K
- IMRN 73.4K
- Earning Date
- ADIL 11-12-2025
- IMRN 08-29-2025
- Dividend Yield
- ADIL N/A
- IMRN N/A
- EPS Growth
- ADIL N/A
- IMRN N/A
- EPS
- ADIL N/A
- IMRN N/A
- Revenue
- ADIL N/A
- IMRN $4,777,422.00
- Revenue This Year
- ADIL N/A
- IMRN N/A
- Revenue Next Year
- ADIL N/A
- IMRN N/A
- P/E Ratio
- ADIL N/A
- IMRN N/A
- Revenue Growth
- ADIL N/A
- IMRN 48.63
- 52 Week Low
- ADIL $0.22
- IMRN $1.50
- 52 Week High
- ADIL $1.30
- IMRN $2.73
- Technical
- Relative Strength Index (RSI)
- ADIL 58.88
- IMRN 76.46
- Support Level
- ADIL $0.37
- IMRN $1.87
- Resistance Level
- ADIL $0.41
- IMRN $1.95
- Average True Range (ATR)
- ADIL 0.02
- IMRN 0.07
- MACD
- ADIL 0.01
- IMRN 0.03
- Stochastic Oscillator
- ADIL 75.00
- IMRN 89.36
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.